IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10532051 B1

PDFFull Text
Date of Patent:
Jan. 14, 2020

Filed:

Oct. 05, 2015

Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor 9 (ccr9) and anti-α4β7 integrin blocking antibodies

Applicant:

Chemocentryx, Inc., Mountain View, CA (US);

Inventors:

Karen Ebsworth, San Francisco, CA (US);

Yu Wang, Palo Alto, CA (US);

Yibin Zeng, Foster City, CA (US);

Penglie Zhang, Foster City, CA (US);

Joanne Tan, San Francisco, CA (US);

Assignee:

CHEMOCENTRYX, INC., Mountain View, CA (US);

Attorney:

Brinks Gilson & Lione

Primary Examiner:

Robert H Havlin

Int. Cl.
CPC ...
A61K 31/502 (2006.01); A61K 31/4412 (2006.01); A61K 31/4709 (2006.01); A61K 31/517 (2006.01); A61K 31/415 (2006.01); A61K 31/5377 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 1/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/502 (2013.01); A61K 31/415 (2013.01); A61K 31/4412 (2013.01); A61K 31/4709 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 39/395 (2013.01); A61P 1/00 (2018.01); C07K 16/2842 (2013.01);
Abstract

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.

Find Patent Forward Citations

Loading…